Metadata record for the manuscript: Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational therapy combinations
Creators: name: Labrie, Marilyne
name: Li, Allen
name: Creason, Allison
name: Betts, Courtney
name: Keck, Jamie
name: Johnson, Brett
name: Sivagnanam, Shamilene
name: Boniface, Christopher
name: Ma, Hongli
name: Blucher, Aurora
name: Chang, Young Hwan
name: Chin, Koei
name: Vuky, Jacqueline
name: Guimaraes, Alexander R.
name: Downey, Molly
name: Gao, Lina
name: Siex, Kiara
name: Parmar, Swapnil
name: Kolodzie, Annette
name: Spellman, Paul T
name: Goecks, Jeremy
name: Coussens, Lisa M.
name: Corless, Christopher L.
name: Bergan, Raymond
name: Gray, Joe W.
name: Mills, Gordon B.
name: Mitri, Zahi I.
Publisher: name: figshare
Year: 2021
Subjects: subject: 69999 Biological Sciences not elsewhere classified
subject: FOS: Biological sciences
subject: 111299 Oncology and Carcinogenesis not elsewhere classified
subject: FOS: Clinical medicine
subject: Cancer
subject: 111204 Cancer Therapy (excl. Chemotherapy and Radiation Therapy)
subject: 119999 Medical and Health Sciences not elsewhere classified
subject: FOS: Other medical sciences

description: <b>Summary</b><br> This metadata record provides details of the data supporting the claims of the related manuscript: “Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational therapy combinations”. The related study evaluated the feasibility of real-time deep analysis of serial tumour samples from triple negative breast cancer patients to identify mechanisms of resistance and treatment opportunities as they emerge under therapeutic stress engendered by poly-ADP-ribose polymerase (PARP) inhibitors (PARPi). Type of data: real-time deep analysis of serial tumor samples from triple negative breast cancer patients Subject of data: <i>Homo sapiens</i> Sample size: 3 Population characteristics: Eligibility criteria included biopsy proven metastatic triple negative breast cancer, ECOG PS ≤2, received ≤2 chemotherapeutic agents in the metastatic setting. Patients with prior PARP inhibtior or immune checkpoint blockade exposure in the metastatic setting were excluded. Recruitment: Patients for this study were enrolled at Oregon Health and Science University Center for Health and Healing and Community Hematology and Oncology clinics. Trial registration number: https://clinicaltrials.gov/ct2/show/NCT03544125 <b>Data access</b> The raw DNA sequencing data generated during the current study, are available in the <i>European Nucleotide Archive (ENA)</i> at the following accession: https://identifiers.org/ena.embl:EGAS00001005479. As these files are controlled access, researchers must request access to the <i>ENA </i>data. The repository also includes clinical and phenotypic metadata and molecular data (including protein expression). The reverse phase protein array data (protein expression data), are also available via <i>ENA</i>. HER2 immunohistochemistry data, Intracellular Signaling Protein Panel assay data, and data from the GeneTrails Solid Tumor Panel assay, are not publicly available, but will be made available on reasonable request. Please contact the Knight Diagnostic Laboratories at Oregon Health and Science University (OHSU), email: KDLClientServices@ohsu.edu, for more information on these datasets. <b> </b> <b>Corresponding author(s) for this study</b> Zahi I. Mitri, MD, MS; Oregon Health &amp; Science University, 3181 SW Sam Jackson Park Rd. Mail Code: OC14HO, Portland, OR 97239. E-mail: mitri@ohsu.edu. Marilyne Labrie, PhD; Oregon Health &amp; Science University, 2720 S Moody Avenue: Mailcode: KR-PM, Portland, OR 97201. E-mail: labriem@ohsu.edu. <br> <b>Study approval </b> OHSU Institutional Review Board